Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Bioinformation
Prif Awduron: Arannilewa1, Abiodun Julius, Suleiman Alakanse, Oluwaseun, Adesola, Adesola Oluwaseun, Israel Malachi, Oluwaseyi, Michael Obaidu, Ifedayo, Oluwafemi, Emmanuel Ekun, Damilola Afolayan, Emmanuel, Folakemi Afere, Patricia, Abdullateef Ayuba, Kayode, Oluwafemi Bolarinwa, Tolulope, Oche Ambrose, George
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Biomedical Informatics 2018
Pynciau:
Hypothesis
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://ncbi.nlm.nih.gov/pubmed/31223207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6026/97320630014482
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg